The Fort Worth Press - The scientist rewriting DNA, and the future of medicine

USD -
AED 3.672504
AFN 64.000125
ALL 83.571528
AMD 379.306739
ANG 1.790083
AOA 916.999762
ARS 1394.493963
AUD 1.418842
AWG 1.8
AZN 1.701861
BAM 1.70403
BBD 2.026631
BDT 123.441516
BGN 1.709309
BHD 0.377519
BIF 2983.464413
BMD 1
BND 1.284852
BOB 6.95265
BRL 5.263199
BSD 1.006257
BTN 93.307018
BWP 13.64595
BYN 3.067036
BYR 19600
BZD 2.023756
CAD 1.372145
CDF 2270.000154
CHF 0.791955
CLF 0.023189
CLP 915.62992
CNY 6.87305
CNH 6.899385
COP 3706.28
CRC 469.967975
CUC 1
CUP 26.5
CVE 96.081456
CZK 21.300603
DJF 179.186419
DKK 6.509415
DOP 60.835276
DZD 132.532596
EGP 52.246006
ERN 15
ETB 157.116838
EUR 0.87109
FJD 2.218299
FKP 0.749449
GBP 0.75261
GEL 2.71503
GGP 0.749449
GHS 10.968788
GIP 0.749449
GMD 74.000291
GNF 8818.979979
GTQ 7.707255
GYD 210.505219
HKD 7.838665
HNL 26.6321
HRK 6.559102
HTG 131.875123
HUF 342.832038
IDR 16965
ILS 3.10005
IMP 0.749449
INR 93.02915
IQD 1318.032101
IRR 1314999.999493
ISK 124.740309
JEP 0.749449
JMD 157.992201
JOD 0.708996
JPY 159.678503
KES 130.250451
KGS 87.450143
KHR 4029.54184
KMF 427.999782
KPW 899.9784
KRW 1498.698999
KWD 0.30657
KYD 0.838475
KZT 485.403559
LAK 21591.404221
LBP 90120.825254
LKR 313.313697
LRD 184.128893
LSL 16.795929
LTL 2.95274
LVL 0.60489
LYD 6.420803
MAD 9.415922
MDL 17.543921
MGA 4190.776631
MKD 53.654672
MMK 2100.10344
MNT 3571.101739
MOP 8.123072
MRU 40.161217
MUR 46.510055
MVR 15.459929
MWK 1744.806191
MXN 17.80125
MYR 3.933503
MZN 63.898703
NAD 16.795929
NGN 1358.930199
NIO 37.027516
NOK 9.58355
NPR 149.303937
NZD 1.717898
OMR 0.384502
PAB 1.006169
PEN 3.436114
PGK 4.341518
PHP 60.083498
PKR 281.091833
PLN 3.720219
PYG 6503.590351
QAR 3.658789
RON 4.435702
RSD 102.323983
RUB 83.873907
RWF 1468.813316
SAR 3.754684
SBD 8.04524
SCR 15.186236
SDG 600.999678
SEK 9.394075
SGD 1.281845
SHP 0.750259
SLE 24.650034
SLL 20969.510825
SOS 575.063724
SRD 37.374989
STD 20697.981008
STN 21.350297
SVC 8.803744
SYP 110.58576
SZL 16.800579
THB 32.739843
TJS 9.62383
TMT 3.5
TND 2.960823
TOP 2.40776
TRY 44.320504
TTD 6.820677
TWD 31.954598
TZS 2603.730041
UAH 44.250993
UGX 3785.225075
UYU 40.745194
UZS 12269.740855
VES 450.94284
VND 26315.5
VUV 119.592862
WST 2.733704
XAF 571.627633
XAG 0.013074
XAU 0.000206
XCD 2.70255
XCG 1.813334
XDR 0.710924
XOF 571.630124
XPF 103.919416
YER 238.575012
ZAR 16.938598
ZMK 9001.245332
ZMW 19.677217
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • BCE

    -0.2600

    25.75

    -1.01%

  • CMSD

    0.0100

    22.89

    +0.04%

  • RIO

    -2.0800

    87.72

    -2.37%

  • BTI

    -2.4600

    58.09

    -4.23%

  • GSK

    -1.3500

    52.06

    -2.59%

  • BCC

    -1.0800

    71.84

    -1.5%

  • NGG

    -3.0200

    87.4

    -3.46%

  • RELX

    -0.4300

    33.86

    -1.27%

  • CMSC

    -0.1200

    22.83

    -0.53%

  • AZN

    -2.8700

    188.42

    -1.52%

  • RYCEF

    -0.2100

    16.6

    -1.27%

  • JRI

    -0.1370

    12.323

    -1.11%

  • VOD

    -0.3800

    14.37

    -2.64%

  • BP

    0.7600

    44.61

    +1.7%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: © Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

C.M.Harper--TFWP